Chromoblastomycosis caused by Fonsecaea pedrosoi: a case report and literature review
-
By
-
Yuyun Wang
-
Lu Wang
-
Zhen Li
-
Yuanqing Qu
-
Yuan Liu
-
May 28, 2026
-
Clinical Scorecard: A Case Study and Literature Review on Chromoblastomycosis Induced by Fonsecaea pedrosoi
At a Glance
| Category | Detail |
|---|
| Condition | Chromoblastomycosis (CBM) |
| Key Mechanisms | Caused by dematiaceous fungi, primarily Fonsecaea pedrosoi. |
| Target Population | Immunocompromised patients, particularly those with chronic conditions. |
| Care Setting | Dermatology clinics and hospitals. |
Key Highlights
- CBM often misdiagnosed due to non-specific clinical manifestations.
- Immunocompromised patients experience prolonged disease course.
- Diagnosis confirmed through mycological, histopathological, and molecular examinations.
Guideline-Based Recommendations
Diagnosis
- Utilize mycological and histopathological examinations for accurate diagnosis.
Management
- Implement appropriate antifungal treatment based on culture results.
Monitoring & Follow-up
- Regular follow-up to assess treatment efficacy and disease progression.
Risks
- Delayed diagnosis can lead to chronic infection and complications.
Patient & Prescribing Data
Immunocompromised individuals with chronic skin lesions.
Empiric antifungal treatment may be ineffective; specific treatment based on culture results is crucial.
Clinical Best Practices
- Enhance awareness of CBM among healthcare providers.
- Consider CBM in differential diagnosis for chronic skin lesions in endemic regions.
Related Resources & Content
